MedTrace Logo

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

NCT05511766 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-04-13

No results posted yet for this study

Summary

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

Conditions

  • Cirrhosis
  • Hepatic Encephalopathy
  • Ascites
  • Varices
  • SBP - Spontaneous Bacterial Peritonitis

Interventions

DRUG

Allopurinol 300 MG

a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation

DRUG

Atorvastatin 20mg

is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties

DRUG

Placebo

not containing drugs

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • khadija glal · assistant lecturer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-04-25
Completion
2025-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511766 on ClinicalTrials.gov